Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States-Reference-Cited by-同舟云学术

Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States

Published:2021-10 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Dhakal Prajwal^ORCID,Lyden Elizabeth,Joshi Utsav^ORCID,Pyakuryal Avantika,Gundabolu Krishna,Zeidan Amer M.,Loh Kah Poh^ORCID,Fisher Alfred L.^ORCID,Bhatt Vijaya Raj

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference43 articles.

1. Acute promyelocytic leukemia;Hillestad;Acta Med Scand,1957

2. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab;Abaza;Blood,2017

3. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial;Iland;Lancet Haematol,2015

4. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia;Lo-Coco;New Engl J Med,2013

5. Improved Outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial;Platzbecker;J Clin Oncol,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection;Surgical Oncology Insight;2024-03

2. Effect of Age and Socioeconomic Factors in the Utilization of Chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER Database Study of 16,196 Patients;Clinical Lymphoma Myeloma and Leukemia;2022-10